High blood pressure or hypertension, is a widespread issue affecting about 1.3 billion people globally. It is the leading ...

Renin acts on its substrate, angiotensinogen, to generate angiotensin I which is rapidly converted to angiotensin II, a potent vasoconstrictor and the major stimulus of aldosterone production and ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and ...

Renin converts the precursor angiotensinogen to angiotensin I, while ACE further converts it to angiotensin II — a potent vasoconstrictor among other things — leading to an increase in blood ...

Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen. Circ. Res. 94(6), 843–849 (2004).

Despite advancements in umbilical cord blood transplants, social determinants of health, such as poverty and public insurance, continue to impact outcomes, underscoring the need for equitable ...

Professor Thomas Lüscher discusses challenges and opportunities in cardiovascular care, his ESC Congress highlights and the ...

4a), was effective in lowering blood pressure and reducing end-organ damage in double transgenic rats engineered to express human renin and angiotensinogen genes 82. In October 2005, Speedel ...

Woods DR, Pollard AJ, Collier DJ, Jamshidi Y, Vassiliou V, Hawe E, Humphries S, Montgomery HE. Insertion/deletion polymorphism of the angiotensinogen I-converting enzyme gene and arterial oxygen ...

The Company continues to advance two additional preclinical programs, CTX340™ targeting angiotensinogen (AGT) for the treatment of refractory hypertension and CTX450™ targeting 5 ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...